GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3394)

  • GC69677 structure
    GC69677MAX-10181
    CAS: 2171558-14-6
    Purity: >98.00%

    MAX-10181(PD-1/PD-L1-IN-30)は、PD-1/PD-L1結合阻害剤であり、IC50値は0.018μMです。MAX-10181はがんやその他関連疾患の研究に使用されます。

  • GC69705 structure
    GC69705Physalin A
    CAS: 23027-91-0
    Purity: >98.00%

    Physalin Aは、 Physalis alkekengi var franchetiiから分離されたウィタノリドです。 Physalin Aは細胞のアポトーシスを誘導し、caspase-3およびcaspase-8の発現を上昇させます。また、Physalin Aは自己食作用を誘導し、HT1080細胞のアポトーシスに対抗することがわかりました。Physalin Aにはがん疾患の研究に潜在的な可能性があります。

  • GC69795 structure
    GC69795(Rac)-BIO8898
    CAS: 402564-79-8
    Purity: >98.00%

    (Rac)-BIO8898は、CD40-CD154共刺激相互作用を抑制する薬剤です。 (Rac)-BIO8898は、CD154とCD40-Igの結合を抑制し、IC50値は25μMです。

  • GC69801 structure
    GC69801Ragifilimab
    CAS: 2207590-51-8
    Purity: >95.00%

    ラジフィリマブ(INCAGN-1876)は、糖皮質ステロイド誘導性TNFR関連タンパク質(GITR)を標的とする刺激剤モノクローナル抗体です。ラジフィリマブは、進行期または転移性の実質腫瘍の研究に使用されます。

  • GC69841 structure
    GC69841Rubropunctatin
    CAS: 514-67-0
    Purity: >98.00%

    Rubropunctatinは、赤カビから発酵米(赤カビ米)から抽出されたオレンジ色のニトロゲンヘテロ環化合物です。 Rubropunctatinには、抗炎症作用、免疫抑制作用、抗酸化作用があり、また抗腫瘍活性も示します。

  • GC69884 structure
    GC69884Shepherdin (79-87) (TFA)
    Purity: >98.00%

    Shepherdin(79-87)TFAは、Shepherdinの79から87のアミノ酸断片です。Shepherdinは、Hsp90-Survivin複合体のペプチド拮抗剤であり、抗がん活性を持っています。

  • GC69899 structure
    GC69899SIRT6 activator 12q
    CAS: 2601734-99-8
    Purity: >98.00%

    SIRT6 activator 12qは選択的なSIRT6活性化剤である(IC₅₀ = 0.58μM)。

  • GC69912 structure
    GC69912SLC7A11-IN-1
    Purity: >95.00%

    SLC7A11-IN-1は、有効なSLC7A11阻害剤です。SLC7A11-IN-1には抗増殖活性があります。また、細胞浸潤や転移を抑制する作用も示します。さらに、SLC7A11-IN-1は細胞のアポトーシス誘導やS期での細胞周期停止を引き起こすことが報告されています。そのため、SLC7A11-IN-1には抗腫瘍活性があると考えられています。

  • GC69934 structure
    GC69934Spartalizumab
    CAS: 1935694-88-4
    Purity: >98.00%

    Spartalizumab(PDR001)は、PD-1に対してアナモール活性を持つ人工合成の免疫グロブリンG4単クローン抗体であり、PD-L1およびPD-L2との相互作用を阻害します。Spartalizumabは甲状腺未分化癌(ATC)の研究に使用されます。

  • GC69968 structure
    GC69968Sulanemadlin
    CAS: 1451199-98-6
    Purity: >96.50%

    Sulanemadlinはp53標的に基づいた膜浸透性で、有力な大環状ペプチド模倣化合物であり、安定したα-螺旋状のペプチドである。

  • GC70026 structure
    GC70026Thymidine 3',5'-diphosphate tetrasodium
    CAS: 118675-87-9
    Purity: >97.00%

    チミジン3'、5'-二リン酸(デオキシチミジン3′、5′-二リン酸)テトラナトリウムは、スタファイロコッカス核酸酵素および1つのチューダー構造ドメイン(SND1、マイクロRNA調節複合体RISCサブユニット)と[3,5-2H2]チロシル核酸酵素([3,5-2H2] tyrosyl nuclease)の選択的阻害剤です。 チミジン3 ', 5 '-二リン酸テトラナトリウムには抗腫瘍活性があり、生化学反応では触媒剤としても使用できます。

  • GC70039 structure
    GC70039TNF-α (46-65), human TFA
    Purity: >98.00%

    TNF-α(46-65)、ヒト(TFA)は、人間のTNF-αのペプチド断片です。

  • GC70104 structure
    GC70104Utomilumab
    CAS: 1417318-27-4
    Purity: >99.00%

    Utomilumab(PF 05082566)は、T細胞の共刺激受容体4-1BB / CD137をターゲットとする人工化されたIgG2 mAbアゴニストです。 Utomilumabは、再発/難治性のリンパ腫および他のCD20 +非ホジキンリンパ腫(NHL)の研究に使用できます。

  • GC70114 structure
    GC70114Venetoclax-d8
    CAS: 1257051-06-1
    Purity: >99.50%

    Venetoclax-d8は、Venetoclaxの重水素代物です。Venetoclax(ABT-199;GDC-0199)は、選択的で口服可能なBcl-2阻害剤であり、Ki値が0.01nM未満の高い効率を持ちます。 Venetoclaxは自己食作用を誘導することができます。

  • GC70137 structure
    GC70137Vudalimab
    CAS: 2329669-72-7
    Purity: >99.00%

    Vudalimabは、有効なPD-1およびCTLA-4二重阻害剤であり、完全に人源化された双特異性モノクローナル抗体です。Vudalimabは免疫チェックポイント受容体PD-1およびCTLA-4を標的とし、腫瘍選択的T細胞の活性化を促進します。

  • GC70145 structure
    GC70145WL12
    Purity: >98.00%

    WL12は、特異的なターゲットとしてプログラムされた細胞死因子1(PD-L1)に結合するペプチドです。 WL12は、さまざまな放射性同位体を用いて放射性標識が可能であり、腫瘍のPD-L1発現を評価するための放射性トレーサーを生成します。

  • GC70242 structure
    GC70242Thymocartin TFA

    Thymocartin TFAはチミンペプチドのTFA塩形態である。

  • GC70257 structure
    GC70257Gallium maltolate
    CAS: 108560-70-9
    Purity: >98.00%

    Gallium maltolate(GAM)は抗がん性および抗炎症性活性を有するアポトーシス誘導剤である。

  • GC70289 structure
    GC70289AC-VEID-CHO TFA
    Purity: >98.00%

    AC-VEID-CHO TFAはペプチド由来のカスパーゼ阻害剤であり、カスパーゼ6、カスパーゼ3、カスパーゼ7に対してそれぞれ16.2 nm、13.6 nm、162.1 nmのic50値を有する。

  • GC70298 structure
    GC70298Peginterferon beta-1a
    CAS: 1211327-92-2

    Peginterferon β-1aは最初のポリエチレングリコールインターフェロンβ−1 a分子である。

  • GC70332 structure
    GC70332(+)-Erinacin A
    CAS: 156101-08-5
    Purity: >99.00%

    (+)-Erinacin Aは、キノコキノコキノコから分離できる抗がん化合物である。

  • GC70388 structure
    GC70388Justicidin B
    CAS: 17951-19-8
    Purity: >99.00%

    Justicidin Bは強力な抗がんリグニンとアポトーシス促進剤である。

  • GC70411 structure
    GC70411Nrf2-Activator-12G
    CAS: 1554271-18-9
    Purity: >99.00%

    Nrf2-Activator-12G(compd 12 g)はNrf 2の活性化剤である。

  • GC70418 structure
    GC70418Cipepofol
    CAS: 1637741-58-2
    Purity: >98.00%

    Cipepofol(Ciprol)は新規な2,6−二置換フェノール誘導体であり、GABAA受容体の陽変性調節剤と直接作動剤である。